Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 16/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486273 | 0.81 | DAO (1.00) | DAO | |
| SCHEMBL14485993 | 0.80 | DAO (0.56) | DAOGLALMNA | |
| SCHEMBL14486306 | 0.77 | DAO (0.76) | DAO | |
| SCHEMBL14485917 | 0.77 | DAO (0.67) | DAOLMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL14486223 | 0.77 | DAO (1.00) | DAO | |
| SCHEMBL14485880 | 0.76 | DAO (0.61) | DAO | |
| SCHEMBL14488187 | 0.75 | DAO (0.58) | DAOLMNAKDM4E | |
| SCHEMBL14486127 | 0.75 | DAO (0.64) | DAO | |
| SCHEMBL14486325 | 0.75 | DAO (1.00) | DAO | |
| SCHEMBL14486534 | 0.74 | DAO (0.76) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | claimed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | claimed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | claimed |
| EP-2729453-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | claimed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | claimed |
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2729453-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TPMT, DHFR, DPYD | DAO 934/4885GLA 3208/4885LMNA 3191/4885 |
| US-10085986-B2 | Pyrimidinone compounds and their use | TPMT, DHFR, DPYD | DAO 934/4885GLA 3208/4885LMNA 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.